These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8911655)

  • 21. Clinical aspects of autoimmune rheumatic diseases.
    Goldblatt F; O'Neill SG
    Lancet; 2013 Aug; 382(9894):797-808. PubMed ID: 23993190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of altered prenatal hormonal environment on expression of autoimmune disease in NZB/NZW mice.
    Walker SE; Keisler LW; Caldwell CW; Kier AB; vom Saal FS
    Environ Health Perspect; 1996 Aug; 104 Suppl 4(Suppl 4):815-21. PubMed ID: 8880004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of early inflammatory arthritis. Intervention with immunomodulatory agents: T cell vaccination.
    Kingsley G; Panayi GS
    Baillieres Clin Rheumatol; 1992 Jun; 6(2):435-54. PubMed ID: 1525847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunomodulation and immunomodulators].
    Mimori T; Homma M
    Nihon Rinsho; 1981 Apr; 39(4):1847-51. PubMed ID: 7031296
    [No Abstract]   [Full Text] [Related]  

  • 25. Tolerance defects in New Zealand Black and New Zealand Black X New Zealand White F1 mice.
    McCoy KL; Kendrick L; Chused TM
    J Immunol; 1986 Feb; 136(4):1217-22. PubMed ID: 3944456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle.
    Colafrancesco S; Agmon-Levin N; Perricone C; Shoenfeld Y
    Immunol Res; 2013 Jul; 56(2-3):200-5. PubMed ID: 23733136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Photopheresis: new immunomodulatory therapy for T-lymphocite mediated diseases].
    Vagace Valero JM; Alonso Escobar N; De Argila Fernández-Durán D; Vargas Pérez L; Melero Ruiz J; Morán Penco JM; Bajo Gómez R; Pérez Miranda M
    An Med Interna; 2003 Aug; 20(8):421-6. PubMed ID: 14516265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulating agents and hepatic drug-metabolizing enzymes.
    Descotes J
    Drug Metab Rev; 1985; 16(1-2):175-84. PubMed ID: 3905318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thymic hormone in the treatment of cancer.
    Dardeene M; Bach JF
    Prog Clin Biol Res; 1989; 288():363-82. PubMed ID: 2654955
    [No Abstract]   [Full Text] [Related]  

  • 30. Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA.
    Steinberg BJ; Smathers PA; Frederiksen K; Steinberg AD
    J Clin Invest; 1982 Sep; 70(3):587-97. PubMed ID: 6980900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunomodulatory effects of neurotropin through the recovery of interleukin-2 production in autoimmune-prone (NZB/NZW) F1 mice.
    Naiki M; Suehiro S; Imai Y; Osawa T
    Int J Immunopharmacol; 1989; 11(6):663-71. PubMed ID: 2807638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of rheumatism with hormonal preparations].
    ORLOVA AN
    Ter Arkh; 1955; 27(7):75-84. PubMed ID: 13299157
    [No Abstract]   [Full Text] [Related]  

  • 33. [Immunomodulation with apheresis technics].
    Liebert A; Quietzsch D; Zimmermann S
    Allerg Immunol (Leipz); 1986; 32(1):5-18. PubMed ID: 2940851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapeutic approaches in autoimmune rheumatic diseases, with special emphasis on rheumatoid arthritis.
    Kalden JR; Manger B
    Br J Rheumatol; 1995 Mar; 34(3):193-6. PubMed ID: 7728390
    [No Abstract]   [Full Text] [Related]  

  • 35. Dendritic cells as targets or therapeutics in rheumatic autoimmune disease.
    Thomas R
    Curr Opin Rheumatol; 2014 Mar; 26(2):211-8. PubMed ID: 24389864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor-targeted immunotherapy.
    Janson RW; Arend WP
    Bull Rheum Dis; 1992; 41(3):6-8. PubMed ID: 1617334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Requirement of H-2 heterozygosity for autoimmunity in (NZB X NZW)F1 hybrid mice.
    Hirose S; Ueda G; Noguchi K; Okada T; Sekigawa I; Sato H; Shirai T
    Eur J Immunol; 1986 Dec; 16(12):1631-3. PubMed ID: 2949983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases.
    Pyne D; Ehrenstein M; Morris V
    Rheumatology (Oxford); 2002 Apr; 41(4):367-74. PubMed ID: 11961165
    [No Abstract]   [Full Text] [Related]  

  • 39. Advances in autoimmune rheumatic diseases.
    Lancet; 2013 Aug; 382(9894):744. PubMed ID: 23993175
    [No Abstract]   [Full Text] [Related]  

  • 40. The contribution of NZW genes to lupus-like disease in (NZB x NZW)F1 mice.
    Kotzin BL; Palmer E
    J Exp Med; 1987 May; 165(5):1237-51. PubMed ID: 3494806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.